{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:05:44Z","timestamp":1792083944406,"version":"4.4.0"},"reference-count":202,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2019,10,4]]},"DOI":"10.18632\/aging.102355","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T21:44:20Z","timestamp":1570225460000},"page":"8048-8067","source":"Crossref","is-referenced-by-count":194,"title":["Rapamycin for longevity: opinion article"],"prefix":"10.18632","volume":"11","author":[{"given":"Mikhail V.","family":"Blagosklonny","sequence":"first","affiliation":[{"name":"Cell Stress Biology Roswell Park Cancer Institute, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2019,10,4]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1126\/science.1244360","article-title":"mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome.","volume":"34","author":"Ramos","year":"2013","journal-title":"Science"},{"key":"2","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.4161\/cc.5.18.3288","article-title":"Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition.","volume":"5","author":"Blagosklonny","year":"2006","journal-title":"Cell Cycle"},{"key":"3","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.drudis.2007.01.004","article-title":"An anti-aging drug today: from senescence-promoting genes to anti-aging pill.","volume":"1","author":"Blagosklonny","year":"2007","journal-title":"Drug Discov Today"},{"key":"4","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.1158\/0008-5472.CAN-16-0091","article-title":"Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor \u03b3\u03b4 T Cells.","volume":"7","author":"Curiel","year":"2016","journal-title":"Cancer Res"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1479627","article-title":"Clinically-Relevant Rapamycin Treatment Regimens Enhance CD8Effector Memory T Cell Function In The Skin and Allow their Infiltration into Cutaneous Squamous Cell Carcinoma.","volume":"7","author":"Wells","year":"2018","journal-title":"OncoImmunology"},{"key":"6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.18632\/aging.100619","article-title":"Immunostimulatory activity of lifespan-extending agents.","volume":"5","author":"Senovilla","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/2326-6066.CIR-18-0336","article-title":"Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.","volume":"7","author":"Shu","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009892","article-title":"mTOR inhibition improves immune function in the elderly.","volume":"6","author":"Klickstein","year":"2014","journal-title":"Sci Transl Med"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaq1564","article-title":"TORC1 inhibition enhances immune function and reduces infections in the elderly.","volume":"1","author":"Klickstein","year":"2018","journal-title":"Sci Transl Med"},{"key":"10","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.transproceed.2008.03.084","article-title":"Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials.","volume":"4","author":"Singh","year":"2008","journal-title":"Transplant Proc"},{"key":"11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1097\/01.tp.0000290686.68910.bd","article-title":"A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus.","volume":"8","author":"Bara","year":"2007","journal-title":"Transplantation"},{"key":"12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/tid.12601","article-title":"Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients.","volume":"1","author":"Aguado","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"13","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/ni.2741","article-title":"The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus.","volume":"1","author":"Doherty","year":"2013","journal-title":"Nat Immunol"},{"key":"14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1158\/2326-6066.CIR-13-0046","article-title":"mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA.","volume":"1","author":"Sahin","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"15","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.4049\/jimmunol.1001176","article-title":"Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses.","volume":"18","author":"Ford","year":"2010","journal-title":"J Immunol"},{"key":"16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/acel.12380","article-title":"Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice.","volume":"1","author":"Hasty","year":"2015","journal-title":"Aging Cell"},{"key":"17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.exger.2012.08.013","article-title":"Enteric-delivered rapamycin enhances resistance of aged mice to pneumococcal pneumonia through reduced cellular senescence.","volume":"4","author":"Orihuela","year":"2012","journal-title":"Exp Gerontol"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006635","article-title":"Influenza virus differentially activates mTORC1 and mTORC2 signaling to maximize late stage replication.","volume":"1","author":"Fontoura","year":"2017","journal-title":"PLoS Pathog"},{"key":"19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ebiom.2018.05.027","article-title":"Comprehending a Killer: The Akt\/mTOR Signaling Pathways Are Temporally High-Jacked by the Highly Pathogenic 1918 Influenza Virus.","volume":"3","author":"Kobasa","year":"2018","journal-title":"EBioMedicine"},{"key":"20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.","volume":"1","author":"Friend","year":"2004","journal-title":"Clin Transplant"},{"key":"21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.","volume":"8","author":"Kahan","year":"2005","journal-title":"Transplantation"},{"key":"22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.","volume":"1","author":"Brault","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation.","volume":"36","author":"Hofbauer","year":"2012","journal-title":"N Engl J Med"},{"key":"24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.","volume":"3","author":"Hofbauer","year":"2018","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.3892\/or.2015.4277","article-title":"Early and delayed intervention with rapamycin prevents NNK-induced lung adenocarcinoma in A\/J mice.","volume":"3","author":"Rao","year":"2015","journal-title":"Oncol Rep"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112774","article-title":"mTOR and Aging: An Old Fashioned Dress.","volume":"2","author":"Grandaliano","year":"2019","journal-title":"Int J Mol Sci"},{"key":"27","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.4161\/cbt.7.10.6663","article-title":"Prevention of cancer by inhibiting aging.","volume":"7","author":"Blagosklonny","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"28","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/1078-0432.CCR-06-2570","article-title":"Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.","volume":"1","author":"Dennis","year":"2007","journal-title":"Clin Cancer Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1158\/1055-9965.EPI-07-0045","article-title":"The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention.","volume":"1","author":"Crowell","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ajpath.2012.03.017","article-title":"Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug.","volume":"18","author":"Pestell","year":"2012","journal-title":"Am J Pathol"},{"key":"31","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.celrep.2014.05.039","article-title":"Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.","volume":"7","author":"Dennis","year":"2014","journal-title":"Cell Rep"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26961","article-title":"Immunosuppressants in cancer prevention and therapy.","volume":"2","author":"Blagosklonny","year":"2013","journal-title":"OncoImmunology"},{"key":"33","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.2353\/ajpath.2010.091050","article-title":"Rapamycin extends maximal lifespan in cancer-prone mice.","volume":"17","author":"Blagosklonny","year":"2010","journal-title":"Am J Pathol"},{"key":"34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.18632\/aging.100498","article-title":"Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+\/- mice.","volume":"4","author":"Gudkov","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1940-6207.CAPR-13-0299","article-title":"eRapa restores a normal life span in a FAP mouse model.","volume":"7","author":"Sharp","year":"2014","journal-title":"Cancer Prev Res (Phila)"},{"key":"36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.18632\/aging.100533","article-title":"Rapamycin extends life span of Rb1+\/- mice by inhibiting neuroendocrine tumors.","volume":"5","author":"Sharp","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"37","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1007\/s00018-014-1677-1","article-title":"Longevity, aging and rapamycin.","volume":"7","author":"Xie","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41419-019-1822-8","article-title":"Fasting and rapamycin: diabetes versus benevolent glucose intolerance.","volume":"1","author":"Blagosklonny","year":"2019","journal-title":"Cell Death Dis"},{"key":"39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1083\/jcb.200408161","article-title":"Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis.","volume":"16","author":"Manning","year":"2004","journal-title":"J Cell Biol"},{"key":"40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cmet.2006.05.003","article-title":"Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.","volume":"3","author":"Thomas","year":"2006","journal-title":"Cell Metab"},{"key":"41","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism.","volume":"12","author":"Hall","year":"2006","journal-title":"Cell"},{"key":"42","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.","volume":"12","author":"Huber","year":"2011","journal-title":"J Clin Invest"},{"key":"43","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing.","volume":"1","author":"Sabatini","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.gde.2012.12.005","article-title":"mTOR in aging, metabolism, and cancer.","volume":"2","author":"Hall","year":"2013","journal-title":"Curr Opin Genet Dev"},{"key":"45","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.2337\/db06-1016","article-title":"The Mammalian target of rapamycin pathway regulates nutrient-sensitive glucose uptake in man.","volume":"5","author":"Roden","year":"2007","journal-title":"Diabetes"},{"key":"46","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.2337\/diabetes.54.9.2674","article-title":"Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability.","volume":"5","author":"Roden","year":"2005","journal-title":"Diabetes"},{"key":"47","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/cbin.11015","article-title":"Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy.","volume":"4","author":"Ye","year":"2018","journal-title":"Cell Biol Int"},{"key":"48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s00125-004-1662-6","article-title":"Regulation of insulin signalling by hyperinsulinaemia: role of IRS-1\/2 serine phosphorylation and the mTOR\/p70 S6K pathway.","volume":"4","author":"Saad","year":"2005","journal-title":"Diabetologia"},{"key":"49","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.18632\/aging.101117","article-title":"Rapamycin treatment benefits glucose metabolism in mouse models of type 2 diabetes.","volume":"8","author":"Harrison","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.molimm.2016.01.008","article-title":"Rapamycin\/GABA combination treatment ameliorates diabetes in NOD mice.","volume":"7","author":"Chen","year":"2016","journal-title":"Mol Immunol"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.178","article-title":"Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.","volume":"5","author":"Blagosklonny","year":"2014","journal-title":"Cell Death Dis"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092684","article-title":"Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice.","volume":"9","author":"Wolowczuk","year":"2014","journal-title":"PLoS One"},{"key":"53","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00109-011-0834-3","article-title":"Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity.","volume":"9","author":"Jan","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"54","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.","volume":"33","author":"Baur","year":"2012","journal-title":"Science"},{"key":"55","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.2337\/db09-1324","article-title":"Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.","volume":"5","author":"Marette","year":"2010","journal-title":"Diabetes"},{"key":"56","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1111\/j.1476-5381.2011.01716.x","article-title":"Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.","volume":"16","author":"Foti","year":"2012","journal-title":"Br J Pharmacol"},{"key":"57","first-page":"533","article-title":"Metabolic abnormalities in starvation diabetes.","volume":"2","author":"Lundbaek","year":"1948","journal-title":"Yale J Biol Med"},{"key":"58","first-page":"705","article-title":"Starvation Diabetes, The Reason for the Use of Glucose in the Treatment of Diabetic Acidosis.","volume":"1","author":"Peters","year":"1945","journal-title":"Yale J Biol Med"},{"key":"59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11357-009-9118-z","article-title":"Effects of long-term calorie restriction and endurance exercise on glucose tolerance, insulin action, and adipokine production.","volume":"3","author":"Holloszy","year":"2010","journal-title":"Age (Dordr)"},{"key":"60","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1111\/dme.12116","article-title":"Population response to information on reversibility of Type 2 diabetes.","volume":"3","author":"Taylor","year":"2013","journal-title":"Diabet Med"},{"key":"61","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/dme.12722","article-title":"Restoring normoglycaemia by use of a very low calorie diet in long- and short-duration Type 2 diabetes.","volume":"3","author":"Taylor","year":"2015","journal-title":"Diabet Med"},{"key":"62","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cmet.2018.07.003","article-title":"Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for \u03b2 Cell Recovery.","volume":"2","author":"Lean","year":"2018","journal-title":"Cell Metab"},{"key":"63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/1056-8727(94)00077-8","article-title":"Starvation diet and very-low-calorie diets may induce insulin resistance and overt diabetes mellitus.","volume":"1","author":"Kisch","year":"1996","journal-title":"J Diabetes Complications"},{"key":"64","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1080\/15384101.2019.1644765","article-title":"The mystery of the ketogenic diet: benevolent pseudo-diabetes.","volume":"1","author":"Blagosklonny","year":"2019","journal-title":"Cell Cycle"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2016.2","article-title":"A low-carbohydrate high-fat diet increases weight gain and does not improve glucose tolerance, insulin secretion or \u03b2-cell mass in NZO mice.","volume":"6","author":"Andrikopoulos","year":"2016","journal-title":"Nutr Diabetes"},{"key":"66","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2016.31","article-title":"What are we to think when results from mouse research contradict those from human experiments and clinical practice?","volume":"6","author":"Thornley","year":"2016","journal-title":"Nutr Diabetes"},{"key":"67","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1590\/2359-3997000000177","article-title":"Low carbohydrate high fat diets: when models do not match reality.","volume":"6","author":"Lima","year":"2016","journal-title":"Arch Endocrinol Metab"},{"key":"68","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.18632\/aging.102180","article-title":"clinical trials for anti-aging therapies.","volume":"1","author":"Alarc\u00f3n","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"69","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.18632\/aging.100401","article-title":"Intermittent supplementation with rapamycin as a dietary restriction mimetic.","volume":"3","author":"Fontana","year":"2011","journal-title":"Aging (Albany NY)"},{"key":"70","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.arr.2011.11.005","article-title":"Of mice and men: the benefits of caloric restriction, exercise, and mimetics.","volume":"1","author":"de Cabo","year":"2012","journal-title":"Ageing Res Rev"},{"key":"71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.12834","article-title":"Manipulation of health span and function by dietary caloric restriction mimetics.","volume":"136","author":"Ingram","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"72","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.4161\/cc.10.24.18595","article-title":"Rapamycin-induced glucose intolerance: hunger or starvation diabetes.","volume":"1","author":"Blagosklonny","year":"2011","journal-title":"Cell Cycle"},{"key":"73","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/gerona\/glu238","article-title":"Rapamycin Versus Intermittent Feeding: Dissociable Effects on Physiological and Behavioral Outcomes When Initiated Early and Late in Life.","volume":"7","author":"Morgan","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"74","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1172\/JCI44774","article-title":"Role of mTOR in podocyte function and diabetic nephropathy in humans and mice.","volume":"12","author":"Nelson","year":"2011","journal-title":"J Clin Invest"},{"key":"75","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/j.1523-1755.2005.00433.x","article-title":"Gas6 induces Akt\/mTOR-mediated mesangial hypertrophy in diabetic nephropathy.","volume":"6","author":"Arai","year":"2005","journal-title":"Kidney Int"},{"key":"76","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.2353\/ajpath.2007.070412","article-title":"Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin.","volume":"17","author":"Kasinath","year":"2007","journal-title":"Am J Pathol"},{"key":"77","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1097\/TP.0b013e3181a192bd","article-title":"Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.","volume":"8","author":"Hugo","year":"2009","journal-title":"Transplantation"},{"key":"78","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1681\/ASN.2005050549","article-title":"Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.","volume":"1","author":"Griny\u00f3","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"79","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1159\/000106782","article-title":"Rapamycin prevents early steps of the development of diabetic nephropathy in rats.","volume":"2","author":"Chen","year":"2007","journal-title":"Am J Nephrol"},{"key":"80","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.bbrc.2005.12.012","article-title":"Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice.","volume":"34","author":"Kashiwagi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"81","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.bbrc.2009.04.136","article-title":"The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential.","volume":"38","author":"Yoshimura","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"82","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.lfs.2010.06.004","article-title":"The combination of sirolimus and rosiglitazone produces a renoprotective effect on diabetic kidney disease in rats.","volume":"8","author":"Cruzado","year":"2010","journal-title":"Life Sci"},{"key":"83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114324","article-title":"Rapamycin ameliorates nephropathy despite elevating hyperglycemia in a polygenic mouse model of type 2 diabetes, NONcNZO10\/LtJ.","volume":"9","author":"Harrison","year":"2014","journal-title":"PLoS One"},{"key":"84","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.4161\/cc.10.20.17686","article-title":"mTOR in podocyte function: is rapamycin good for diabetic nephropathy?","volume":"1","author":"Guan","year":"2011","journal-title":"Cell Cycle"},{"key":"85","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1093\/ndt\/gfi181","article-title":"Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).","volume":"2","author":"W\u00fcthrich","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"86","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.exger.2017.12.026","article-title":"A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.","volume":"10","author":"Kellogg","year":"2018","journal-title":"Exp Gerontol"},{"key":"87","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3109\/0284186X.2016.1168939","article-title":"Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.","volume":"5","author":"Wu","year":"2016","journal-title":"Acta Oncol"},{"key":"88","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.clgc.2016.04.011","article-title":"Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.","volume":"1","author":"Brechenmacher","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"89","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1507\/endocrj.EJ18-0542","article-title":"The clinical course and potential underlying mechanisms of everolimus-induced hyperglycemia.","volume":"6","author":"Takamura","year":"2019","journal-title":"Endocr J"},{"key":"90","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1016\/j.transproceed.2015.09.006","article-title":"Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.","volume":"4","author":"Olivares","year":"2015","journal-title":"Transplant Proc"},{"key":"91","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/j.transproceed.2008.06.005","article-title":"New-onset diabetes mellitus after kidney transplantation: the role of immunosuppression.","volume":"4","author":"Veroux","year":"2008","journal-title":"Transplant Proc"},{"key":"92","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1159\/000288232","article-title":"Sirolimus-based immunosuppression in kidney transplantation for type 2 diabetic nephropathy.","volume":"8","author":"Veroux","year":"2010","journal-title":"Urol Int"},{"key":"93","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13024","article-title":"Switch to an everolimus-facilitated cyclosporine A sparing immunosuppression improves glycemic control in selected kidney transplant recipients.","volume":"3","author":"Sommerer","year":"2017","journal-title":"Clin Transplant"},{"key":"94","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0140-6736(05)70914-4","article-title":"New-onset diabetes after transplantation: a threat to graft and patient survival.","volume":"36","author":"Wheeler","year":"2005","journal-title":"Lancet"},{"key":"95","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.transproceed.2018.01.028","article-title":"Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus.","volume":"5","author":"Yagisawa","year":"2018","journal-title":"Transplant Proc"},{"key":"96","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/496974","article-title":"Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation.","volume":"201","author":"Veroux","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"97","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1681\/ASN.2007111202","article-title":"Sirolimus is associated with new-onset diabetes in kidney transplant recipients.","volume":"1","author":"Gill","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"98","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1681\/ASN.2008050474","article-title":"Diabetes after transplantation and sirolimus: what\u2019s the connection?","volume":"1","author":"Goldfarb-Rumyantzev","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"99","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-12-0110","article-title":"Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.","volume":"1","author":"Undevia","year":"2012","journal-title":"Clin Cancer Res"},{"key":"100","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2215\/CJN.03671106","article-title":"Transplant-associated hyperglycemia: a new look at an old problem.","volume":"2","author":"Bloom","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"101","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/annonc\/mdu225","article-title":"Estimates of benefits and harms of prophylactic use of aspirin in the general population.","volume":"2","author":"Rothwell","year":"2015","journal-title":"Ann Oncol"},{"key":"102","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10654-014-9971-7","article-title":"Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population.","volume":"3","author":"Cuzick","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128033","article-title":"Acute sirolimus overdose: a multicenter case series.","volume":"1","author":"Taegtmeyer","year":"2015","journal-title":"PLoS One"},{"key":"104","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/00007691-200010000-00006","article-title":"Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers.","volume":"2","author":"Groth","year":"2000","journal-title":"Ther Drug Monit"},{"key":"105","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1093\/ndt\/gfm420","article-title":"Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.","volume":"2","author":"Rump","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"106","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/JLB.3AB0616-251RRR","article-title":"Mammalian target of rapamycin regulates a hyperresponsive state in pulmonary neutrophils late after burn injury.","volume":"10","author":"Maile","year":"2018","journal-title":"J Leukoc Biol"},{"key":"107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0093691","article-title":"Single rapamycin administration induces prolonged downward shift in defended body weight in rats.","volume":"9","author":"Blundell","year":"2014","journal-title":"PLoS One"},{"key":"108","doi-asserted-by":"publisher","first-page":"ra75","DOI":"10.1126\/scisignal.2000559","article-title":"mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells.","volume":"2","author":"Zheng","year":"2009","journal-title":"Sci Signal"},{"key":"109","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7554\/eLife.16351","article-title":"Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.","volume":"5","author":"Beyer","year":"2016","journal-title":"eLife"},{"key":"110","doi-asserted-by":"publisher","first-page":"44876","DOI":"10.18632\/oncotarget.10381","article-title":"Rapamycin in aging and disease: maximizing efficacy while minimizing side effects.","volume":"7","author":"Kaeberlein","year":"2016","journal-title":"Oncotarget"},{"key":"111","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fgene.2015.00247","article-title":"Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice.","volume":"6","author":"Sangesland","year":"2015","journal-title":"Front Genet"},{"key":"112","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.4161\/15384101.2014.970491","article-title":"Comparison of rapamycin schedules in mice on high-fat diet.","volume":"1","author":"Blagosklonny","year":"2014","journal-title":"Cell Cycle"},{"key":"113","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jgg.2014.06.009","article-title":"Rapamycin and ageing: when, for how long, and how much?","volume":"4","author":"Kaeberlein","year":"2014","journal-title":"J Genet Genomics"},{"key":"114","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1089\/rej.2008.0722","article-title":"Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells.","volume":"1","author":"Blagosklonny","year":"2008","journal-title":"Rejuvenation Res"},{"key":"115","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/gerona\/glw064","article-title":"Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL\/6J Mice.","volume":"7","author":"Lamming","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"116","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1023\/B:BGEN.0000006561.15498.68","article-title":"\u201cI thought, thought, thought for four months in vain and suddenly the idea came\u201d--an interview with Denham and Helen Harman. Interview by K. Kitani and G.O. Ivy.","volume":"4","author":"Harman","year":"2003","journal-title":"Biogerontology"},{"key":"117","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.4161\/cc.7.21.6965","article-title":"Aging: ROS or TOR.","volume":"7","author":"Blagosklonny","year":"2008","journal-title":"Cell Cycle"},{"key":"118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00018-009-0138-8","article-title":"When a theory of aging ages badly.","volume":"6","author":"Hekimi","year":"2010","journal-title":"Cell Mol Life Sci"},{"key":"119","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2203\/dose-response.13-035.Ristow","article-title":"Mitohormesis: Promoting Health and Lifespan by Increased Levels of Reactive Oxygen Species (ROS).","volume":"1","author":"Schmeisser","year":"2014","journal-title":"Dose Response"},{"key":"120","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-physiol-030212-183712","article-title":"Genetics of longevity in model organisms: debates and paradigm shifts.","volume":"7","author":"Partridge","year":"2013","journal-title":"Annu Rev Physiol"},{"key":"121","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/ars.2012.4840","article-title":"Alternative Perspectives on Aging in Caenorhabditis elegans: Reactive Oxygen Species or Hyperfunction?","volume":"1","author":"de la Guardia","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"122","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1196\/annals.1354.004","article-title":"The free radical fantasy: a panoply of paradoxes.","volume":"106","author":"Howes","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"123","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1001\/jama.297.8.842","article-title":"Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.","volume":"29","author":"Gluud","year":"2007","journal-title":"JAMA"},{"key":"124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007176.pub2","article-title":"Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.","volume":"3","author":"Gluud","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0074558","article-title":"Meta-regression analyses, meta-analyses, and trial sequential analyses of the effects of supplementation with beta-carotene, vitamin A, and vitamin E singly or in different combinations on all-cause mortality: do we have evidence for lack of harm?","volume":"8","author":"Gluud","year":"2013","journal-title":"PLoS One"},{"key":"126","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/MCO.0000000000000009","article-title":"Antioxidant supplements and mortality.","volume":"1","author":"Gluud","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"127","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/bmj.39350.500428.47","article-title":"Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis.","volume":"33","author":"Guymer","year":"2007","journal-title":"BMJ"},{"key":"128","doi-asserted-by":"publisher","first-page":"f10","DOI":"10.1136\/bmj.f10","article-title":"Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials.","volume":"34","author":"Park","year":"2013","journal-title":"BMJ"},{"key":"129","doi-asserted-by":"publisher","first-page":"8665","DOI":"10.1073\/pnas.0903485106","article-title":"Antioxidants prevent health-promoting effects of physical exercise in humans.","volume":"10","author":"Bl\u00fcher","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"130","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.freeradbiomed.2011.05.010","article-title":"Extending life span by increasing oxidative stress.","volume":"5","author":"Schmeisser","year":"2011","journal-title":"Free Radic Biol Med"},{"key":"131","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJM199605023341802","article-title":"Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.","volume":"33","author":"Hammar","year":"1996","journal-title":"N Engl J Med"},{"key":"132","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/jnci\/djh320","article-title":"The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.","volume":"9","author":"Williams","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"133","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/cncr.22482","article-title":"Effects of alpha-tocopherol and beta-carotene supplementation on upper aerodigestive tract cancers in a large, randomized controlled trial.","volume":"10","author":"Albanes","year":"2007","journal-title":"Cancer"},{"key":"134","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature15726","article-title":"Oxidative stress inhibits distant metastasis by human melanoma cells.","volume":"52","author":"Morrison","year":"2015","journal-title":"Nature"},{"key":"135","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007653","article-title":"Antioxidants accelerate lung cancer progression in mice.","volume":"6","author":"Bergo","year":"2014","journal-title":"Sci Transl Med"},{"key":"136","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad3740","article-title":"Antioxidants can increase melanoma metastasis in mice.","volume":"7","author":"Bergo","year":"2015","journal-title":"Sci Transl Med"},{"key":"137","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1210\/er.2018-00216","article-title":"Growth hormone deficiency: health and longevity.","volume":"4","author":"Bartke","year":"2019","journal-title":"Endocr Rev"},{"key":"138","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.1096\/fj.10-163253","article-title":"Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice.","volume":"2","author":"Masternak","year":"2010","journal-title":"FASEB J"},{"key":"139","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fgene.2018.00586","article-title":"Impact of Growth Hormone-Related Mutations on Mammalian Aging.","volume":"9","author":"Quainoo","year":"2018","journal-title":"Front Genet"},{"key":"140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199007053230101","article-title":"Effects of human growth hormone in men over 60 years old.","volume":"32","author":"Mattson","year":"1990","journal-title":"N Engl J Med"},{"key":"141","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1056\/NEJMp020186","article-title":"Can growth hormone prevent aging?","volume":"34","author":"Vance","year":"2003","journal-title":"N Engl J Med"},{"key":"142","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1126\/science.1115535","article-title":"Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients.","volume":"31","author":"Kennedy","year":"2005","journal-title":"Science"},{"key":"143","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/426620a","article-title":"Genetics: influence of TOR kinase on lifespan in C. elegans.","volume":"42","author":"M\u00fcller","year":"2003","journal-title":"Nature"},{"key":"144","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.cub.2004.03.059","article-title":"Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway.","volume":"1","author":"Benzer","year":"2004","journal-title":"Curr Biol"},{"key":"145","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.bbagen.2009.06.007","article-title":"The TOR pathway comes of age.","volume":"179","author":"Kennedy","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"146","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/sj.embor.embor806","article-title":"Cell senescence and hypermitogenic arrest.","volume":"4","author":"Blagosklonny","year":"2003","journal-title":"EMBO Rep"},{"key":"147","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.4161\/cc.7.21.6919","article-title":"Growth stimulation leads to cellular senescence when the cell cycle is blocked.","volume":"7","author":"Blagosklonny","year":"2008","journal-title":"Cell Cycle"},{"key":"148","doi-asserted-by":"publisher","first-page":"281","DOI":"10.18632\/aging.100034","article-title":"Validation of anti-aging drugs by treating age-related diseases.","volume":"1","author":"Blagosklonny","year":"2009","journal-title":"Aging (Albany NY)"},{"key":"149","doi-asserted-by":"publisher","first-page":"861","DOI":"10.18632\/aging.100525","article-title":"Answering the ultimate question \u201cwhat is the proximal cause of aging?\u201d.","volume":"4","author":"Blagosklonny","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"150","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.18632\/aging.101647","article-title":"Disease or not, aging is easily treatable.","volume":"1","author":"Blagosklonny","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"151","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.4161\/cc.27188","article-title":"Aging is not programmed: genetic pseudo-program is a shadow of developmental growth.","volume":"1","author":"Blagosklonny","year":"2013","journal-title":"Cell Cycle"},{"key":"152","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.18632\/aging.101486","article-title":"Monsters in the uterus: teratoma-like tumors in senescentresult from a parthenogenetic quasi-program.","volume":"1","author":"Gems","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"153","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.4161\/cc.9.10.11872","article-title":"Rapamycin and quasi-programmed aging: four years later.","volume":"9","author":"Blagosklonny","year":"2010","journal-title":"Cell Cycle"},{"key":"154","doi-asserted-by":"publisher","first-page":"35492","DOI":"10.18632\/oncotarget.18033","article-title":"From rapalogs to anti-aging formula.","volume":"8","author":"Blagosklonny","year":"2017","journal-title":"Oncotarget"},{"key":"155","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nature08221","article-title":"Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.","volume":"46","author":"Miller","year":"2009","journal-title":"Nature"},{"key":"156","doi-asserted-by":"publisher","first-page":"31688","DOI":"10.3402\/pba.v6.31688","article-title":"Adaptations to chronic rapamycin in mice.","volume":"6","author":"Sharp","year":"2016","journal-title":"Pathobiol Aging Age Relat Dis"},{"key":"157","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.18632\/aging.101289","article-title":"Rapamycin in mice.","volume":"9","author":"Swindell","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"158","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ajpath.2012.06.024","article-title":"Prospective treatment of age-related diseases by slowing down aging.","volume":"18","author":"Blagosklonny","year":"2012","journal-title":"Am J Pathol"},{"key":"159","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.520","article-title":"Koschei the immortal and anti-aging drugs.","volume":"5","author":"Blagosklonny","year":"2014","journal-title":"Cell Death Dis"},{"key":"160","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cell.2013.02.035","article-title":"Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.","volume":"15","author":"Gems","year":"2013","journal-title":"Cell"},{"key":"161","doi-asserted-by":"publisher","first-page":"6","DOI":"10.7554\/eLife.31268","article-title":"Metformin extendslifespan through lysosomal pathway.","volume":"6","author":"Liu","year":"2017","journal-title":"eLife"},{"key":"162","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.bcp.2009.06.018","article-title":"Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats.","volume":"7","author":"Pesquero","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"163","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.4161\/cc.26928","article-title":"Metformin: do we finally have an anti-aging drug?","volume":"1","author":"Anisimov","year":"2013","journal-title":"Cell Cycle"},{"key":"164","doi-asserted-by":"publisher","first-page":"39398","DOI":"10.18632\/oncotarget.6347","article-title":"Metformin for cancer and aging prevention: is it a time to make the long story short?","volume":"6","author":"Anisimov","year":"2015","journal-title":"Oncotarget"},{"key":"165","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/ijc.31016","article-title":"Risk of Cause-Specific Death in Individuals with Cancer-Modifying Role Diabetes, Statins and Metformin.","volume":"14","author":"Auvinen","year":"2017","journal-title":"Int J Cancer"},{"key":"166","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing metformin for the prevention of cancer and cancer recurrence.","volume":"6","author":"Ford","year":"2017","journal-title":"Diabetologia"},{"key":"167","doi-asserted-by":"publisher","first-page":"9017","DOI":"10.18632\/oncotarget.14794","article-title":"Metformin: a metabolic modulator.","volume":"8","author":"Kroemer","year":"2017","journal-title":"Oncotarget"},{"key":"168","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ajog.2017.06.003","article-title":"Metformin, the aspirin of the 21st century: its\u00a0role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and\u00a0the promotion of longevity.","volume":"21","author":"Grossman","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"169","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41416-018-0039-4","article-title":"Progress in preventive therapy for cancer: a reminiscence and personal viewpoint.","volume":"11","author":"Cuzick","year":"2018","journal-title":"Br J Cancer"},{"key":"170","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1158\/1940-6207.CAPR-17-0015","article-title":"Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice.","volume":"1","author":"Browning","year":"2017","journal-title":"Cancer Prev Res (Phila)"},{"key":"171","doi-asserted-by":"publisher","first-page":"386","DOI":"10.18632\/aging.101401","article-title":"Metformin reduces glucose intolerance caused by rapamycin treatment in genetically heterogeneous female mice.","volume":"1","author":"Salmon","year":"2018","journal-title":"Aging (Albany NY)"},{"key":"172","doi-asserted-by":"publisher","first-page":"990","DOI":"10.2105\/AJPH.92.6.990","article-title":"Benefits of smoking cessation for longevity.","volume":"9","author":"Sloan","year":"2002","journal-title":"Am J Public Health"},{"key":"173","first-page":"136","article-title":"Is late-life caloric restriction beneficial?","volume":"7","author":"Blumberg","year":"1995","journal-title":"Aging (Milano)"},{"key":"174","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mad.2005.09.001","article-title":"Caloric restriction in humans: potential pitfalls and health concerns.","volume":"12","author":"Leeuwenburgh","year":"2006","journal-title":"Mech Ageing Dev"},{"key":"175","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10522-006-9011-4","article-title":"Health span extension by later-life caloric or dietary restriction: a view based on rodent studies.","volume":"7","author":"Goto","year":"2006","journal-title":"Biogerontology"},{"key":"176","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1046\/j.1532-5415.2001.49258.x","article-title":"Weight change in old age and its association with mortality.","volume":"4","author":"Fried","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"177","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1532-5415.2010.03245.x","article-title":"Mortality risk in older men associated with changes in weight, lean mass, and fat mass.","volume":"5","author":"Orwoll","year":"2011","journal-title":"J Am Geriatr Soc"},{"key":"178","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/archinte.165.9.1035","article-title":"Reasons for intentional weight loss, unintentional weight loss, and mortality in older men.","volume":"16","author":"Lennon","year":"2005","journal-title":"Arch Intern Med"},{"key":"179","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/nature09584","article-title":"mTORC1 controls fasting-induced ketogenesis and its modulation by ageing.","volume":"46","author":"Sabatini","year":"2010","journal-title":"Nature"},{"key":"180","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.biocel.2016.06.012","article-title":"High mTORC1 signaling is maintained, while protein degradation pathways are perturbed in old murine skeletal muscles in the fasted state.","volume":"7","author":"Shavlakadze","year":"2016","journal-title":"Int J Biochem Cell Biol"},{"key":"181","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/acel.12109","article-title":"Late-life rapamycin treatment reverses age-related heart dysfunction.","volume":"1","author":"Melov","year":"2013","journal-title":"Aging Cell"},{"key":"182","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glz060","article-title":"Is Rapamycin a Dietary Restriction Mimetic?","author":"Richardson","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"183","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/gerona\/gls127","article-title":"Short-term treatment with rapamycin and dietary restriction have overlapping and distinctive effects in young mice.","volume":"6","author":"P\u00e9rez","year":"2013","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"184","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/acel.12175","article-title":"Combined treatment of rapamycin and dietary restriction has a larger effect on the transcriptome and metabolome of liver.","volume":"1","author":"P\u00e9rez","year":"2014","journal-title":"Aging Cell"},{"key":"185","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/gerona\/glu053","article-title":"Rapamycin and dietary restriction induce metabolically distinctive changes in mouse liver.","volume":"7","author":"P\u00e9rez","year":"2015","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"186","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/acel.12317","article-title":"Subacute calorie restriction and rapamycin discordantly alter mouse liver proteome homeostasis and reverse aging effects.","volume":"1","author":"Rabinovitch","year":"2015","journal-title":"Aging Cell"},{"key":"187","doi-asserted-by":"publisher","first-page":"539","DOI":"10.18632\/aging.100576","article-title":"Rapamycin doses sufficient to extend lifespan do not compromise muscle mitochondrial content or endurance.","volume":"5","author":"Baur","year":"2013","journal-title":"Aging (Albany NY)"},{"key":"188","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.18632\/aging.102176","article-title":"Rapamycin protects aging muscle.","volume":"1","author":"Goldman","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"189","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00141-19","article-title":"Partial inhibition of mTORC1 in aged rats counteracts the decline in muscle mass and reverses molecular signaling associated with sarcopenia.","volume":"3","author":"Glass","year":"2019","journal-title":"Mol Cell Biol"},{"key":"190","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12943","article-title":"mTORC1 underlies age-related muscle fiber damage and loss by inducing oxidative stress and catabolism.","volume":"1","author":"Wang","year":"2019","journal-title":"Aging Cell"},{"key":"191","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.18632\/aging.101319","article-title":"Towards natural mimetics of metformin and rapamycin.","volume":"9","author":"Zhavoronkov","year":"2017","journal-title":"Aging (Albany NY)"},{"key":"192","doi-asserted-by":"publisher","first-page":"547","DOI":"10.18632\/aging.100479","article-title":"How to save Medicare: the anti-aging remedy.","volume":"4","author":"Blagosklonny","year":"2012","journal-title":"Aging (Albany NY)"},{"key":"193","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11357-017-9994-6","article-title":"Rapamycin treatment attenuates age-associated periodontitis in mice.","volume":"3","author":"Kaeberlein","year":"2017","journal-title":"Geroscience"},{"key":"194","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1080\/15548627.2019.1615823","article-title":"Rapamycin and Alzheimer disease: a double-edged sword?","volume":"1","author":"Sargeant","year":"2019","journal-title":"Autophagy"},{"key":"195","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/jnc.13935","article-title":"Endo-lysosomal and autophagic dysfunction: a driving factor in Alzheimer\u2019s disease?","volume":"14","author":"Sargeant","year":"2017","journal-title":"J Neurochem"},{"key":"196","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.18632\/aging.101155","article-title":"Gerosuppression by pan-mTOR inhibitors.","volume":"8","author":"Blagosklonny","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"197","doi-asserted-by":"publisher","first-page":"231","DOI":"10.18632\/aging.100872","article-title":"Reversal of phenotypes of cellular senescence by pan-mTOR inhibition.","volume":"8","author":"Cox","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"198","doi-asserted-by":"publisher","first-page":"9660","DOI":"10.1073\/pnas.1002298107","article-title":"Paradoxical suppression of cellular senescence by p53.","volume":"10","author":"Blagosklonny","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"199","doi-asserted-by":"publisher","first-page":"15802","DOI":"10.18632\/oncotarget.4602","article-title":"p53 and rapamycin are additive.","volume":"6","author":"Hasty","year":"2015","journal-title":"Oncotarget"},{"key":"200","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.4161\/cc.8.12.8809","article-title":"Pharmacologic inhibition of MEK and PI-3K converges on the mTOR\/S6 pathway to decelerate cellular senescence.","volume":"8","author":"Blagosklonny","year":"2009","journal-title":"Cell Cycle"},{"key":"201","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1913212116","article-title":"A triple drug combination targeting components of the nutrient-sensing network maximizes longevity.","author":"Partridge","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"202","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.celrep.2016.03.041","article-title":"Lithium Promotes Longevity through GSK3\/NRF2-Dependent Hormesis.","volume":"1","author":"Partridge","year":"2016","journal-title":"Cell Rep"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.102355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T19:22:09Z","timestamp":1599074529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.102355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,4]]},"references-count":202,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,10,15]]}},"alternative-id":["102355","31586989"],"URL":"https:\/\/doi.org\/10.18632\/aging.102355","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,4]]}}}